Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

PJ Online | News: Move to phase out BANs at end of 2003

Home > PJ (current issue) > News / Daily News | Search

Return to PJ Online Home Page

The Pharmaceutical Journal
Vol 269 No 7215 p352
14 September 2002

This article
Reprint
Photocopy


News summary

Related websites
Medicines Control Agency (www.mca.gov.uk)


Move to phase out BANs at end of 2003

Only names of products containing adrenaline will still use BANs

The Medicines Control Agency is proposing to phase out the use of British Approved Names (BANs) in favour of recommended International Non-proprietary Names (rINNs) starting in December 2003. The only exception would be the continued use of "adrenaline" and "noradrenaline", the most commonly used BANs.

In a consultation letter issued on 4 September, the MCA says that although European law requires the use of rINNs, this has not been strictly applied in the United Kingdom because of the well-established use of BANs and public health concerns about the potential for medication errors if the names of certain critical substances were changed. A previous MCA proposal to switch from BANs to rINNs was withdrawn for legal reasons.

However, the MCA says that there is now a need to clarify the position as other European Union member states routinely use rINNs. Such products can appear in the UK under rules covering mutual recognition of product licences within Europe. In addition, pharmaceutical companies can use rINNs in applications for marketing in the UK. "The confused situation is itself a possible contributory factor to medication errors," the MCA says.

Following consultations with the Medicines Commission and health departments in England, Scotland and Wales, the MCA is now proposing to start phasing out the use of BANs from December 2003. Companies will have 12 months to change their product licences, for which the MCA will charge a fee, or 24 months if the BAN is only used in the summary of product characteristics or patient information leaflet. The MCA believes that such changes will take place alongside routine updates.

For adrenaline and noradrenaline, the MCA will demand that companies currently using rINNs (epinephrine and norepinephrine) change to using BANs for consistency. No fee will be charged for this.

The MCA is seeking comments from interested parties by 18 September ahead of a wider public consultation exercise. Comments can be sent to Chris Bantock, European Support Unit Manager, Medicines Control Agency, Market Towers, 1 Nine Elms Lane, London SW8 5NQ (tel 020 7273 0395, e-mail chris.bantock@mca.gsi.gov.uk).

Back to Top

Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal

Citation: The Pharmaceutical Journal URI: 20007692

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Pharmacy Registration Assessment Questions

    Pharmacy Registration Assessment Questions

    Pharmacy Registration Assessment Questions features over 400 closed book and calculation questions. With the registration exam having gone through a complete transformation in 2016, this volume has been developed around the new General Pharmaceutical Council (GPhC) guidelines.

    £32.00Buy now
  • Dale and Appelbe's Pharmacy and Medicines Law

    Dale and Appelbe's Pharmacy and Medicines Law

    This new edition of Dale and Appelbe's Pharmacy and Medicines Law is the definitive guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. Fully updated to include changes to pharmacy laws and regulation.

    £55.00Buy now
  • Non-medical Prescribing

    Non-medical Prescribing

    An essential new guide designed to ensure confident prescribing in specialist areas.

    £26.00Buy now
  • Foundation in Pharmacy Practice

    Foundation in Pharmacy Practice

    A practical and succinct overview of the principal pharmacy practice topics, for new pharmacy students.

    £32.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £32.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £39.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.